Skip to Content

REVEAL

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

Patient Information

The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.

More details at: http://clinicaltrials.gov/show/NCT01252953

Study Number
NCT01252953

Clinical Trial Categories

  • Secondary Prevention Trials

Also in this Section